Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
Keystone Symposium: Multiple Sclerosis
Pervasive Axonal Transport Deficits in Multiple Sclerosis Models.
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
Power estimation for non-standardized multisite studies.
Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
Incorporating Alcohol Pharmacotherapies Into Medical Practice
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.
Gordon Research Conference on Myelin Biology and Pathobiology of Myelinating Glia
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation.
Gene expression analysis reveals functional pathways of glatiramer acetate activation.
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Dilantin
Autoimmune Hepatitis-like reaction developing in a patient treated with Interferon beta 1a.
Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research.
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
Foxp3(+) Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production.
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study.
Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome.

Pages